论文部分内容阅读
目前做为社会问题的输血后肝炎(非甲非乙型肝炎),尚未建立有效的预防措施,因治疗而输血却引起了肝炎,这对患者、家属、医生都是苦恼的。一般认为输血后肝炎(非甲非乙型肝炎)的发病率是10～20%,心脏外科,特别是采用体外循环作开胸手术时,肝炎发病率为15～60%,幅度较大,有的发病率较高。近几年来,为防止输血后肝炎做了种种努力。从1979年起,作者曾尝试对供血者进行鸟嘌呤酶活性检验,用于筛选,以预防肝炎发病。鸟嘌呤酶的历史很久,是1932年由Schmidt从家兔的肝脏匀浆中发现的一种酶,它是参与鸟嘌呤分解为黄嘌呤时的脱氨基酶,黄嘌呤再由黄嘌呤氧化酶氧化分解为尿酸。
Currently, post-transfusion hepatitis (non-A, non-B hepatitis) as a social issue has not yet been established with effective preventive measures. Blood transfusion caused hepatitis due to treatment, which is distressing to patients, their families and doctors. It is generally believed that the incidence of post-transfusion hepatitis (non-A, non-B) is 10 to 20%. Cardiac surgery, especially when undergoing extracorporeal circulation for thoracic surgery, has a hepatitis incidence of 15-60% The incidence of higher. In recent years, efforts have been made to prevent post-transfusion hepatitis. Since 1979, the authors attempted to test guanosinease activity in donors for screening to prevent the onset of hepatitis. Guanase has a long history and was discovered by Schmidt from liver homogenates of rabbits in 1932. It is a deaminase involved in the decomposition of guanine into xanthine which is then oxidized by xanthine oxidase Break down into uric acid.